Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00318903 · ClinicalTrials.gov registry record · Phase 2
Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00318903 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 25 participants.
The verdict
NCT00318903, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
There is a need for more effective therapy for patients following surgery for esophageal carcinoma. Docetaxel and Irinotecan, independent of each other, have demonstrated activity in this disease. There is interest in the combination of these two active agents plus radiotherapy.
Interventions
- DRUG Irinotecan (drug)
- DRUG Taxotere (drug)
- PROCEDURE Radiotherapy (procedure)
- PROCEDURE Esophagectomy (procedure)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2002-01 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00318903
The ClinicalTrials.gov registry entry for NCT00318903 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Irinotecan (drug) is the first listed.
NCT00318903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00318903 about?
NCT00318903 is a clinical study titled "Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer". There is a need for more effective therapy for patients following surgery for esophageal carcinoma. Docetaxel and Irinotecan, independent of each other, have demonstrated activity in this disease. There is interest in the combination of these two active agents plus radiotherapy.
What is the current status of trial NCT00318903?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2002-01. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00318903?
The interventions under investigation include: Irinotecan (drug) (DRUG), Taxotere (drug) (DRUG), Radiotherapy (procedure) (PROCEDURE), Esophagectomy (procedure) (PROCEDURE).
Who is sponsoring clinical trial NCT00318903?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.